Sort
85,873 grants matching “alzheimers”
Modeling Alzheimer's disease genetic variants in hiPSC
$779,733Jubao Duan · Endeavor Health Clinical Operations · R01 · FY2019 · AG
Novel PET Radiotracer for Muscarinic M1 Receptor
$779,731Yiyun Henry Huang · Yale University · R01 · FY2018 · MH
CHARGE: Identifying Risk & Protective SNV for AD in ADSP Case-control Sample
$779,712Sudha Seshadri · Boston University Medical Campus · U01 · FY2014 · AG
Alzheimer's Disease Risk and Ethnic Factors: The Case of Arab Americans
$779,680Kristine J Ajrouch · University Of Michigan At Ann Arbor · R01 · FY2022 · AG
Investigating Resistance and Resilience Mechanisms in Alzheimerâs Disease
$779,639Prashanthi Vemuri · Mayo Clinic Rochester · R01 · FY2024 · AG
A biomarker-driven trial of angiotensin receptor blockers for prodromal Alzheimer
$779,626Felicia C Goldstein · Emory University · R01 · FY2020 · AG
Identifying and supporting patients with undiagnosed dementia using the EHR Risk of Alzheimer's and Dementia Assessment Rule (eRADAR): a pilot clinical trial
$779,617Sascha Dublin · Kaiser Foundation Research Institute · R01 · FY2021 · AG
Role of Disease-Associated Microglia in Alzheimer's disease
$779,590Kim Green · University Of California-Irvine · R01 · FY2024 · AG
A physiologically relevant pre-clinical drug screening platform for Alzheimer's Disease and Traumatic Brain Injury with integrated stretchable microelectrodes
$779,587Oliver Graudejus · Bmseed, Llc · R44 · FY2025 · AG
Alzheimer's Disease Risk and Ethnic Factors: The Case of Arab Americans
$779,583Kristine J Ajrouch · University Of Michigan At Ann Arbor · R01 · FY2018 · AG
Daily Experiences among Black and White Dementia Caregivers: Implications for Well-being and Cardiovascular Health
$779,559Kira S Birditt · University Of Michigan At Ann Arbor · R01 · FY2019 · AG
Disease Mechanism and Therapy in TDP-43 Proteinopathies and Dementias
$779,544Don W. Cleveland · University Of California, San Diego · R01 · FY2022 · NS
A biomarker-driven trial of angiotensin receptor blockers for prodromal Alzheimer
$779,538Ihab M Hajjar · Emory University · R01 · FY2019 · AG
Preclinical assessment of GCPII inhibitors for cognition and tau pathology
$779,486Amy F.t. Arnsten · Yale University · R01 · FY2021 · AG
Linking olfactory deficits to memory impairment and AD neurodegeneration
$779,466Prasanna Rasika Karunanayaka · Pennsylvania State Univ Hershey Med Ctr · R01 · FY2024 · AG
Drug repositioning for Alzheimer's disease via genetics, electronic health records, and human iPSC models
$779,465Bingshan Li · Vanderbilt University · R01 · FY2024 · AG
Health Beliefs, Glycemic Control, and Preventing Cognitive Decline in African Americans with Diabetes and Mild Cognitive Impairment: A Randomized Clinical Trial
$779,451Barry W Rovner · Thomas Jefferson University · R01 · FY2020 · AG
PET Imaging of Synaptic Density in Alzheimers Disease
$779,436Richard E Carson · Yale University · R01 · FY2019 · AG
Drug repurposing for Alzheimer's disease using structural systems pharmacology.
$779,392Lei Xie · Hunter College · R01 · FY2019 · AG
Drug repurposing for Alzheimer's disease using structural systems pharmacology.
$779,392Lei Xie · Hunter College · R01 · FY2021 · AG
Drug repurposing for Alzheimer's disease using structural systems pharmacology.
$779,392Lei Xie · Hunter College · R01 · FY2020 · AG
Drug repurposing for Alzheimer's disease using structural systems pharmacology.
$779,392Lei Xie · Hunter College · R01 · FY2022 · AG
Drug repurposing for Alzheimer's disease using structural systems pharmacology.
$779,392Lei Xie · Hunter College · R01 · FY2018 · AG
Genetic etiology of Amyotrophic Lateral Sclerosis
$779,377Bryan Traynor · National Institute On Aging · ZIA · FY2014 · AG
CSF Clearance in Sporadic Alzheimer's Disease
$779,375Yi Li · Weill Medical Coll Of Cornell Univ · R01 · FY2022 · AG